Takeda UK Ltd has announced that Adcetris (brentuximab vedotin) has been accepted for restricted use within NHS Scotland for the treatment of adult patients with CD30+ relapsed or refractory Hodgkin lymphoma (HL) following an autologous stem cell transplant (ASCT) or following at least two previous therapies, when ASCT or multi-agent chemotherapy is not a treatment option. The availability of this cancer treatment offers further hope to patients in Scotland with this stage of disease, who have limited effective treatment options remaining.

Commenting on the SMC decision, Dr David Meiklejohn, Consultant Haematologist, Ninewells Hospital, Dundee said “It is great news that eligible patients in Scotland now have access to this innovative treatment option, particularly as patients at this stage of disease can be very difficult to treat effectively with standard treatments. The results seen with brentuximab vedotin in clinical trials and in clinical practice are impressive, with efficacy and safety data that are rarely seen with a single-agent therapy.’

For more details, go to: http://www.firstwordpharma.com/node/1239761?tsid=28&region_id=4#axzz3G1mygRlZ